echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Ascletis Pharma Submits U.S. Clinical Trial Application for Oral PD-L1 Small Molecule Inhibitor

    Ascletis Pharma Submits U.S. Clinical Trial Application for Oral PD-L1 Small Molecule Inhibitor

    • Last Update: 2022-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 10, Ascletis announced that the company has submitted a US clinical trial application (IND) for ASC61, an oral PD-L1 small molecule inhibitor developed by itself, for the treatment of advanced solid tumors


    ASC61 is a potent and highly selective oral PD-L1 small molecule inhibitor that blocks the PD-1/PD-L1 interaction by inducing the formation and endocytosis of PD-L1 dimers


    Compared with PD-1/PD-L1 antibody injections, oral PD-L1 inhibitor ASC61 has the following advantages: (1) convenient administration, no need to go to the hospital for injection drugs; (2) combined with other oral antitumor drugs Form an all-oral treatment regimen; and (3) be able to adjust the dosage in a timely manner to better manage immune-related adverse events


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.